Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in India / NCT06474195
Active, not recruiting Not applicable

Cue-based Intervention in Prospective Memory and Medication Adherence.

NCT06474195 · tracked via the Priya Life Science India tracker
Sponsor
University of Pittsburgh
Phase
Not applicable
Started
2024-06-15
Last updated
2026-06-05

Condition(s) studied

Schizophrenia

Investigational drug(s) / intervention(s)

Cue based interventionTreatment as Usual

Cue based intervention: The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The reminders will be set on participants' mobile phones to receive at least 1 hour prior to the prescribed oral antipsychotic medication. The same reminder will be repeated after 10 minutes duration to ensure that the participant does not miss the cue and the uniformity of the cue will be ensured by setting the same emoji or the same phrase on the participant's own mobile phone. The participant will also be asked a task of daily routine during the same time of medication.

Treatment as Usual: This group will not get any intervention but the usual treatment all assessments will continue

Study summary

Medication adherence is a major challenge while treating patients with major mental illnesses like schizophrenia and schizoaffective disorder. This interventional study aims to assess the improvement in prospective memory and thus medication adherence by giving time and event-based cues to the participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Male and Female age 18 - 60 years * Diagnosed with Schizophrenia as per DSM V Criteria * Insight of grade 3 or more. * At least 10th standard level of education in the English language Exclusion Criteria: * Comorbid chronic medical illnesses. * Psychoactive substance use in harmful use pattern or in dependence pattern. * Co-existing neurodevelopmental disorders or learning disorders.

Primary outcome measure(s)

  • Prospective memory — Baseline, After 30days' intervention
    Change in prospective memory in intervention arm as measured by compared to TAU The Memory for Intentions Screening Test(MIST) score as compared to TAU
  • Prospective memory (sustainability) — Baseline, 90 days after baseline assessment
    Change in prospective memory in intervention arm as measured by compared to TAU The Memory for Intentions Screening Test (MIST) score as compared to TAU
  • Medication adherence — Baseline, After 30days' intervention
    Change in medication adherence in intervention arm as measured by Brief Adherence Rating Scale (BARS) score as compared to TAU
  • Medication adherence (Sustainability) — Baseline, 90 days after baseline assessment
    Change in medication adherence in intervention arm as measured by Brief Adherence Rating Scale (BARS) score as compared to TAU

Trial sites (1)

FacilityCityRegionStatus
St. John's Medical College and Hospital Bengaluru Karnataka

More University of Pittsburgh trials in India

Efficacy of EBPSI on Future Suicide Risk Among Adolescent Suicide Attempters Recruiting
Efficacy of Sleep Hygiene Intervention in Elderly With Insomnia Starting soon
Effect of Yoga on Reducing Craving in Tobacco Dependent Individuals Recruiting
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA Starting soon
Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus Starting soon

Other trials for the same condition

Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents Recruiting
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA Starting soon
Acetazolamide for Treatment Resistant Schizophrenia Recruiting
Prucalopride for Cognitive Functioning in Schizophrenia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06474195 on ClinicalTrials.gov ↗ ← All trials in India